menu search

89bio's low price presents an opportunity

89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive ...

October 26, 2023, 2:15 pm

89bio earns ‘buy' rating in initial coverage on positive prospects for nash therapeutic

Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th...

August 28, 2023, 3:01 pm

89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine

– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and ...

June 24, 2023, 9:05 am

89bio shares rise as analysts see improved outlook for nash treatments

Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the...

June 13, 2023, 8:29 am

Why shares of 89bio soared this week

89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH dru...

March 24, 2023, 10:57 am

Biotech stock surges on mid-stage drug trial success

The shares of 89bio Inc   ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug ...

March 22, 2023, 10:49 am

Why is 89bio (etnb) stock up 34% today?

89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to d...

March 22, 2023, 9:30 am

89bio: a promising nash innovator

As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer a...

March 17, 2023, 6:18 pm

89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...

February 21, 2023, 8:00 am


Search within

Pages Search Results: